The 19th R&D Meeting

March 4, 2022

Sysmex Corporation

Index

1 Opening Presentation

Hisashi Ietsugu

Chairman and CEO

2 R&D Initiatives under the Mid-Term Management Plan

Kaoru Asano

Member of the Managing Board and

Senior Executive Officer

Senior Managing Director, CTO

  1. Creation of New Laboratory Testing Value Based on Hematology
  2. Creation of Clinical Value by Leveraging Cancer Gene Testing Technology
  3. Initiatives for the Realization of Personalized Medicine Glossary

Takaaki Nagai

Executive Officer

Executive Vice President of

System Engineering Div.

Reiko Watanabe

Executive Officer

Executive Vice President of

Medical Affairs Div.

Tomokazu Yoshida

Member of the Managing Board

and Senior Executive Officer

Managing Director

■The information contained in these materials is based on current judgements and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments in Japan and overseas may cause plans to change.

■These materials contain information about products, service and support (including those under development). This information

is not intended for advertising or promotional purposes.

2

1

Opening Presentation

Hisashi Ietsugu

Chairman and CEO

3

Sysmex's Long-Term Management Goals

Long-Term

Management

Goals

(2025)

Mid-Term

Management Plan

(through March 2024)

Long-Term Vision

Unique & Advanced Healthcare Testing Company

Positioning Targets

  • Creating innovative diagnostic value as a global top-five company in IVD
  • A leading company in personalized diagnostics for optimizing medical treatment
  • A solution provider contributing to the advancement of primary care diagnostics
  • An attractive company providing value and instilling confidence
  • One Sysmex carrying out high-speed management

4

Changes in the External Environment

・Changes in healthcare policy (from reducing healthcare costs to

Healthcare

strengthening healthcare infrastructure and improving access)

・Self-medication, digitalization (online medicine, treatment apps)

・Progress of personalized medicine (cancer, dementia)

・Market penetration of PCR tests, and early commercialization of innovative

Technology

technologies such as mRNA vaccines

・Social implementation of digital tools (digitalization, AI, virtual and

augmented reality)

・Technological innovation toward zero carbon (clean energy, power saving)

・Changes in social behavior during and after the COVID-19 pandemic

Society

・Diversifying and increasing social demands, such as SDGs and responses to climate

change

・Greater speed and flexibility being required as uncertainty increases

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sysmex Corporation published this content on 03 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2022 00:05:06 UTC.